Form 4: UTHR CFO Edgemond Exercises Options, Sells Shares

United Therapeutics CFO James Edgemond exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Summary

• James Edgemond, CFO and Treasurer of United Therapeutics Corp (UTHR), exercised 10,000 stock options at an exercise price of $117.76 per share.
• Following the option exercise, Mr. Edgemond sold a total of 9,996 shares of Common Stock in multiple transactions.
• The sale prices for the Common Stock ranged from a weighted average of $561.4823 to $571.4811 per share.
• All transactions, including the option exercise and subsequent sales, occurred on May 28, 2026.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan established by Mr. Edgemond on October 31, 2025.
• After these reported transactions, Mr. Edgemond's direct beneficial ownership of Common Stock stands at 18,876 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider selling can sometimes be perceived negatively, the execution under a pre-planned 10b5-1 trading plan makes it a routine personal financial management activity rather than a signal of company-specific concerns.

Positives

• The CFO exercised stock options, indicating a realization of value from the company's equity compensation.
• All transactions were conducted under a Rule 10b5-1 trading plan, demonstrating pre-planned and transparent insider trading activity, which mitigates concerns about trading on non-public information.

Negatives

• The CFO sold a significant number of shares (9,996 shares), which, while part of a pre-planned strategy, represents a reduction in direct equity exposure to the company's stock.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales by executives, are common for personal financial planning, diversification, or liquidity needs. When executed under a Rule 10b5-1 plan, such transactions are pre-arranged and provide transparency, mitigating concerns about trading on non-public information. This filing represents a routine disclosure for a public company executive managing their equity compensation.

Stakeholder Impact

• Shareholders may note the executive's sale of shares, but the pre-planned nature of the transaction under a 10b5-1 plan typically minimizes any significant negative interpretation or impact on shareholder confidence.

Key Dates

Recommendation

This Form 4 details a routine insider transaction (option exercise and subsequent sale) executed under a pre-planned 10b5-1 trading plan. Such transactions are common for executive compensation and personal financial management and typically do not signal a change in the company's fundamental outlook or warrant a change in investment recommendation. The filing itself provides no new information about the company's operational or financial performance that would alter an existing investment thesis.

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, Stock Options, Share Sale, CFO, James Edgemond, 10b5-1 Plan